SCHEMBL3373118

SCHEMBL3373118

COc1ncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2ccc(C(F)(F)F)n2)cc1C=O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.36
ULK1 O75385 1/20 0.36
STK17A Q9UEE5 3/20 0.36
EGFR P00533 3/20 0.36
STK17B O94768 2/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
FGFR1 P11362 1/20 0.34
MAPK1 P28482 1/20 0.34
PTK2 Q05397 1/20 0.34
AXL P30530 2/20 0.33
BCL6 P41182 1/20 0.33
IDH1 O75874 2/20 0.33
MEN1 O00255 1/20 0.33
PABPC1 P11940 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3452050 0.90 FGFR1 (0.36) APPULK1STK17AEGFRSTK17B
SCHEMBL3452042 0.90 FGFR1 (0.36) APPULK1STK17AEGFRSTK17B
SCHEMBL3374369 0.90 FGFR1 (0.36) APPULK1STK17AEGFRSTK17B
SCHEMBL3374364 0.90 FGFR1 (0.36) APPULK1STK17AEGFRSTK17B
SCHEMBL3448901 0.87 EGFR (0.41) APPULK1EGFRPIK3CDPIK3CA
SCHEMBL3378656 0.87 PTK2 (0.37) APPULK1STK17AEGFRSTK17B
SCHEMBL3451173 0.86 CSF1R (0.42) STK17AEGFRSTK17BPTK2
SCHEMBL3376031 0.86 ULK1 (0.38) APPULK1STK17AEGFRSTK17B
SCHEMBL3447244 0.85 PTK2 (0.42) APPULK1PTK2AXL
SCHEMBL3449613 0.85 PTK2 (0.37) APPULK1STK17AEGFRSTK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD APP 3735/4885ULK1 2054/4885STK17A 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.